The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

NKX2-1 Rearranged Lung Cancer

A molecular subgroup of non-small cell lung cancer with distinct biology and emerging implications

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is NKX2-1 Rearranged Lung Cancer?

NKX2-1, also known as thyroid transcription factor 1, is a master regulator of lung and thyroid development that is widely used in pathology to confirm pulmonary origin of adenocarcinoma. Genomic rearrangement and amplification of NKX2-1 define a distinct biologic subset of lung cancer with implications for diagnosis and prognosis.

Tumors with NKX2-1 alterations may show variable response to standard chemoimmunotherapy and complex interactions with co-occurring driver mutations such as KRAS, EGFR, and TP53. Comprehensive next-generation sequencing detects these structural events that may not be apparent on routine immunohistochemistry alone.

Treatment is currently anchored in standard non-small cell lung cancer pathways with chemotherapy, immune checkpoint inhibitors, and targeted therapy when actionable co-mutations are present. Clinical trial enrollment is encouraged because dedicated NKX2-1-directed therapies are an active area of preclinical and early-phase research.

Symptoms

Persistent cough or hemoptysis
Unexplained weight loss and fatigue
Chest pain or new-onset dyspnea
Pleural effusion or atelectasis on imaging
Brain or bone metastases at diagnosis

Risk Factors

Tobacco smoking history
Adenocarcinoma histology with TTF-1 expression
Co-occurring KRAS or EGFR mutations
TP53 alteration in advanced disease
Family history of pulmonary malignancy

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When a lung mass is identified on imaging
  • When unexplained respiratory symptoms persist
  • When prior diagnosis recurs on surveillance
  • When comprehensive molecular testing is needed
  • When clinical trial enrollment is being considered

Treatment Methods

01
Comprehensive next-generation sequencing at diagnosis
02
Standard chemoimmunotherapy as backbone
03
Targeted therapy for actionable co-mutations
04
Clinical trial enrollment when available
05
Local therapy with surgery or radiation when feasible
06
Brain magnetic resonance imaging surveillance
07
Multidisciplinary review with thoracic oncology

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.